Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Avoiding premature licensing

A Corrigendum to this article was published on 01 February 2007

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Value of biotech out-licensing deals.
Figure 2: Example of a collaborative development financing structure.
Figure 3: Illustrative value creation through collaborative development financing.

Author information

Authors and Affiliations


Ethics declarations

Competing interests

As a result of the financings completed by Symphony Capital Partners and its affiliates listed in Table 1, Mark Kessel and Sam Hall have certain economic interests in the biotech companies listed therein and the respective collaborative partnering companies developing those indications.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kessel, M., Hall, S. Avoiding premature licensing. Nat Rev Drug Discov 5, 985–986 (2006).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing